243 results
20-F/A
2023 FY
IPCIF
Intellipharmaceutics International Inc.
6 Feb 24
Annual report (foreign) (amended)
12:00am
on our business and operations, our programs regarding research, development and commercialization of our product candidates, the timing … in the pharmaceutical industry generally may be regarded as uncertain given the research and development (“R&D”) nature of the industry and uncertainty
6-K
EX-99.2
IPCIF
Intellipharmaceutics International Inc.
16 Oct 23
Current report (foreign)
5:23pm
Licensing (Note 3)
Up-front fees (Note 3)
Cost of revenue
Expenses
Research and development
Selling, general and administrative
Depreciation (Note 4 … in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
On October 22
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
16 Oct 23
Current report (foreign)
5:23pm
) including its impact on our business and operations, our programs regarding research, development and commercialization of our product candidates … of which are currently traded on the TSX and OTCQB.
We are a pharmaceutical company specializing in the research, development and manufacture of novel
6-K
EX-99.3
IPCIF
Intellipharmaceutics International Inc.
16 Oct 23
Current report (foreign)
5:23pm
. (OTCQB: IPCIF and TSX: IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development … Intellipharmaceutics
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel
6-K
EX-99.2
IPCIF
Intellipharmaceutics International Inc.
6 Oct 23
Annual Meeting of Shareholders
11:33am
Discussion and Analysis
Background
The Company is a pharmaceutical company specializing in the research, development and manufacture of novel … in administration and research and development.
Compensation Governance
The Company’s Compensation Committee is comprised of three directors, Messrs
6-K
EX-99.2
ux4o53y yntij
26 Sep 23
Current report (foreign)
5:29pm
6-K
EX-99.3
l59zu uxo
26 Sep 23
Current report (foreign)
5:29pm
6-K
EX-99.1
33v685kzerhe0aqaa
26 Sep 23
Current report (foreign)
5:29pm
6-K
EX-99.2
hcc vrbmgw31
26 Sep 23
Current report (foreign)
5:23pm
6-K
EX-99.1
p6f3r3qx2l8qvzvnpx3g
26 Sep 23
Current report (foreign)
5:23pm
6-K
EX-99.3
59576
26 Sep 23
Current report (foreign)
5:23pm
6-K
EX-99.2
1w4v56mrjmn2rp
14 Oct 22
Current report (foreign)
4:22pm
6-K
EX-99.1
jc5154gr0 ykuzjjw
14 Oct 22
Current report (foreign)
4:22pm
6-K
EX-99.3
9gicikpwkv4endrzxw
14 Oct 22
Current report (foreign)
4:22pm
6-K
EX-99.1
kkt95o1z40
21 Jul 22
Current report (foreign)
5:28pm
6-K
EX-99.3
yzhzy
21 Jul 22
Current report (foreign)
5:28pm
6-K
EX-99.2
rbs8hi77l1vc
21 Jul 22
Current report (foreign)
5:28pm
20-F/A
t4l1uz8s1kkjr 4ybt6
6 May 22
Annual report (foreign) (amended)
7:54pm
6-K
EX-99.2
b5rgjk6gjx
29 Apr 22
Annual & Special Meeting of Shareholders
11:43am